|
1
|
Baskar G, Palaniyandi T, Viswanathan S,
Wahab MRA, Surendran H, Ravi M, Sivaji A, Rajendran BK, Natarajan S
and Govindasamy G: Recent and advanced therapy for oral cancer.
Biotechnol Bioeng. 120:3105–3115. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mehta V, Vilikkathala Sudhakaran S,
Nellore V, Madduri S and Rath SN: 3D stem-like spheroids-on-a-chip
for personalized combinatorial drug testing in oral cancer. J
Nanobiotechnology. 22:3442024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vyas K, Rathod M and Patel MM: Insight on
nano drug delivery systems with targeted therapy in treatment of
oral cancer. Nanomedicine. 49:1026622023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saberian E, Jenča A, Petrášová A,
Zare-Zardini H and Ebrahimifar M: Application of scaffold-based
drug delivery in oral cancer treatment: A novel approach.
Pharmaceutics. 16:8022024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tabassum S: Editorial: PROTACs: Targeted
therapies for cancer treatment. Front Cell Dev Biol.
11:11316382023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chakraborty S, Sharma G, Karmakar S and
Banerjee S: Multi-OMICS approaches in cancer biology: New era in
cancer therapy. Biochim Biophys Acta Mol Basis Dis.
1870:1671202024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Békés M, Langley DR and Crews CM: PROTAC
targeted protein degraders: The past is prologue. Nat Rev Drug
Discov. 21:181–200. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun X, Gao H, Yang Y, He M, Wu Y, Song Y,
Tong Y and Rao Y: PROTACs: Great opportunities for academia and
industry. Signal Transduct Target Ther. 4:642019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li X and Song Y: Proteolysis-targeting
chimera (PROTAC) for targeted protein degradation and cancer
therapy. J Hematol Oncol. 13:502020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gu S, Cui D, Chen X, Xiong X and Zhao Y:
PROTACs: An emerging targeting technique for protein degradation in
drug discovery. BioEssays. 40:e17002472018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu Z and Crews CM: Recent developments in
PROTAC-Mediated protein degradation: From bench to clinic.
Chembiochem. 23:e2021002702022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kubryń N, Fijałkowski Ł, Nowaczyk J, Jamil
A and Nowaczyk A: PROTAC Technology as a new tool for modern
pharmacotherapy. Molecules. 30:21232025. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ibrahim S, Umer Khan M, Khurram I, Rehman
R, Rauf A, Ahmad Z, Aljohani ASM, Al Abdulmonem W and Quradha MM:
Navigating PROTACs in cancer therapy: Advancements, challenges, and
future horizons. Food Sci Nutr. 13:e700112025. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smith BE, Wang SL, Jaime-Figueroa S,
Harbin A, Wang J, Hamman BD and Crews CM: Differential PROTAC
substrate specificity dictated by orientation of recruited E3
ligase. Nat Commun. 10:1312019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li M, Zhi Y, Liu B and Yao Q: Advancing
strategies for proteolysis-targeting chimera design. J Med Chem.
66:2308–2329. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chirnomas D, Hornberger KR and Crews CM:
Protein degraders enter the clinic-a new approach to cancer
therapy. Nat Rev Clin Oncol. 20:265–278. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim
HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et
al: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung
cancer. N Engl J Med. 376:629–640. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guenette RG, Yang SW, Min J, Pei B and
Potts PR: Target and tissue selectivity of PROTAC degraders. Chem
Soc Rev. 51:5740–5756. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rej RK, Allu SR, Roy J, Acharyya RK, Kiran
INC, Addepalli Y and Dhamodharan V: Orally bioavailable
proteolysis-targeting chimeras: An innovative approach in the
golden era of discovering small-molecule cancer drugs.
Pharmaceuticals (Basel). 17:4942024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen Y, Tandon I, Heelan W, Wang Y, Tang W
and Hu Q: Proteolysis-targeting chimera (PROTAC) delivery system:
advancing protein degraders towards clinical translation. Chem Soc
Rev. 51:5330–5350. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang C, Zhang Y, Chen W, Wu Y and Xing D:
New-generation advanced PROTACs as potential therapeutic agents in
cancer therapy. Mol Cancer. 23:1102024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiong Y, Zhong Y, Yim H, Yang X, Park KS,
Xie L, Poulikakos PI, Han X, Xiong Y, Chen X, et al: Bridged
proteolysis targeting chimera (PROTAC) enables degradation of
undruggable targets. J Am Chem Soc. 144:22622–22632. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang X, Song Z, Zhang X, Zou J, Yu G,
Chen X and Wang S: Unconventional PROTACs for targeted protein
degradation in cancer therapy. Angew Chem Int Ed Engl.
64:e2025077022025. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Herrada Céspedes A, Reyes M and Morales
JO: Advanced drug delivery systems for oral squamous cell
carcinoma: A comprehensive review of nanotechnology-based and other
innovative approaches. Front Drug Deliv. 5:15969642025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Špiljak B, Somogyi Škoc M, Rezić Meštrović
I, Bašić K, Bando I and Šutej I: Targeting the oral mucosa:
Emerging drug delivery platforms and the therapeutic potential of
glycosaminoglycans. Pharmaceutics. 17:12122025. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu J, Zheng W, Sun H, González FE, Zhou D
and Xu X: Environment-adaptive microneedle design strategies for
precision oral disease treatment: From material innovation to
clinical translation. J Control Release. 388((Pt 2)): 1144022025.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fang J, Islam W and Maeda H: Exploiting
the dynamics of the EPR effect and strategies to improve the
therapeutic effects of nanomedicines by using EPR effect enhancers.
Adv Drug Deliv Rev. 157:142–160. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Goldberg M, Manzi A, Birdi A, Laporte B,
Conway P, Cantin S, Mishra V, Singh A, Pearson AT, Goldberg ER, et
al: A nanoengineered topical transmucosal cisplatin delivery system
induces anti-tumor response in animal models and patients with oral
cancer. Nat Commun. 13:48292022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Weng Z, Yu J, Liao Y, Zhang Y, Chen C and
Chen W: Emerging Strategies in Smart Nano-PROTAC for
Stimuli-Responsive Protein Degradation and Precision Cancer
Therapy. Nano Biomed Eng. 17:315–332. 2025. View Article : Google Scholar
|
|
30
|
Yang C, Yang Y, Li Y, Ni Q and Li J:
Radiotherapy-triggered proteolysis targeting chimera prodrug
activation in tumors. J Am Chem Soc. 145:385–391. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He Q, Zhou L, Yu D, Zhu R, Chen Y, Song M,
Liu X, Liao Y, Ding T, Fan W and Yu W: Near-infrared-activatable
PROTAC nanocages for controllable target protein degradation and
on-demand antitumor therapy. J Med Chem. 66:10458–10472. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cheng X, Hu S and Cheng K: Microneedle
patch delivery of PROTACs for Anti-cancer therapy. ACS Nano.
17:11855–11868. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ferreira LEN, Franz-Montan M, Benso B and
Gill HS: Microneedles for oral mucosal delivery-Current trends and
perspective on future directions. Expert Opin Drug Deliv.
20:1251–1265. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jin J, Wu Y, Zhao Z, Wu Y, Zhou YD, Liu S,
Sun Q, Yang G, Lin J, Nagle DG, et al: Small-molecule PROTAC
mediates targeted protein degradation to treat STAT3-dependent
epithelial cancer. JCI Insight. 7:e1606062022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zaman SU, Pagare PP, Huang B, Rilee G, Ma
Z, Zhang Y and Li J: Novel PROTAC probes targeting FOSL1
degradation to eliminate head and neck squamous cell carcinoma
cancer stem cells. Bioorg Chem. 151:1076132024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang S, Lai Y, Pan J, Saeed M, Li S, Zhou
H, Jiang X, Gao J, Zhu Y, Yu H, et al: PROTAC prodrug-integrated
nanosensitizer for potentiating radiation therapy of cancer. Adv
Mater. 36:e23141322024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Luffman N, Ahmadinejad F, Finnegan RM,
Raymond M, Gewirtz DA and Harada H: Effectiveness of PROTAC BET
degraders in combating cisplatin resistance in head and neck cancer
cells. Int J Mol Sci. 26:61852025. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Civico-Ortega JL, González-Ruiz I,
Ramos-García P, Cruz-Granados D, Samayoa-Descamps V and
González-Moles MÁ: Prognostic and clinicopathological significance
of epidermal growth factor receptor (EGFR) Expression in oral
squamous cell carcinoma: Systematic review and meta-analysis. Int J
Mol Sci. 24:118882023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Laimer K, Spizzo G, Gastl G, Obrist P,
Brunhuber T, Fong D, Barbieri V, Jank S, Doppler W, Rasse M and
Norer B: High EGFR expression predicts poor prognosis in patients
with squamous cell carcinoma of the oral cavity and oropharynx: A
TMA-based immunohistochemical analysis. Oral Oncol. 43:193–198.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Marconi GD, Della Rocca Y, Fonticoli L,
Melfi F, Rajan TS, Carradori S, Pizzicannella J, Trubiani O and
Diomede F: C-Myc expression in oral squamous cell carcinoma:
Molecular mechanisms in cell survival and cancer progression.
Pharmaceuticals (Basel). 15:8902022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang Y, Yang G, Zhang X, Bai R, Yuan D,
Gao D, He Q, Yuan Y, Zhang X, Kou J, et al: Antitumor effect of
anti-c-Myc aptamer-based PROTAC for degradation of the c-Myc
protein. Adv Sci (Weinh). 11:e23096392024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ramos-Garcia P, González-Moles MÁ,
González-Ruiz L, Ruiz-Ávila I, Ayén Á and Gil-Montoya JA:
Prognostic and clinicopathological significance of cyclin D1
expression in oral squamous cell carcinoma: A systematic review and
meta-analysis. Oral Oncol. 83:96–106. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhao Y, Yu D, Li H, Nie P, Zhu Y, Liu S,
Zhu M and Fang B: Cyclin D1 overexpression is associated with poor
clinicopathological outcome and survival in oral squamous cell
carcinoma in Asian populations: insights from a meta-analysis. PLoS
One. 9:e932102014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Huang SF, Cheng SD, Chuang WY, Chen IH,
Liao CT, Wang HM and Hsieh LL: Cyclin D1 overexpression and poor
clinical outcomes in Taiwanese oral cavity squamous cell carcinoma.
World J Surg Oncol. 10:402012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cai Y, Li H, Xie D and Zhu Y: AKR1B10
accelerates glycolysis through binding HK2 to promote the malignant
progression of oral squamous cell carcinoma. Discov Oncol.
15:1322024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang W, Liu Z, Zhao L, Sun J, He Q, Yan W,
Lu Z and Wang A: Hexokinase 2 enhances the metastatic potential of
tongue squamous cell carcinoma via the SOD2-H2O2 pathway.
Oncotarget. 8:3344–3354. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chakraborty P, Lubna S, Bhuin S,K,D,
Chakravarty M, Jamma T and Yogeeswari P: Targeting hexokinase 2 for
oral cancer therapy: structure-based design and validation of lead
compounds. Front Pharmacol. 15:13462702024. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cho YA, Hong JS, Choe EJ, Yoon HJ, Hong
SD, Lee JI and Hong S: The role of p300 in the tumor progression of
oral squamous cell carcinoma. J Oral Pathol Med. 44:185–192. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhao L, Li P, Zhao L, Wang M, Tong D, Meng
Z, Zhang Q, Li Q and Zhang F: Expression and clinical value of
PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
J Cell Biochem. 121:1855–1869. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yamamoto T, Hirosue A, Nakamoto M, Yoshida
R, Sakata J, Matsuoka Y, Kawahara K, Nagao Y, Nagata M, Takahashi
N, et al: BRD4 promotes metastatic potential in oral squamous cell
carcinoma through the epigenetic regulation of the MMP2 gene. Br J
Cancer. 123:580–590. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wu Y, Wang Y, Diao P, Zhang W, Li J, Ge H,
Song Y, Li Z, Wang D, Liu L, et al: Therapeutic targeting of BRD4
in head neck squamous cell carcinoma. Theranostics. 9:1777–1793.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhao Y, Yang J, Jiang Y and Wu J:
Integrative multi-omics analysis and experimental validation
identify molecular subtypes, prognostic signature, and CA9 as a
therapeutic target in oral squamous cell carcinoma. Front Cell Dev
Biol. 13:16296832025. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hamilton EP, Ma C, De Laurentiis M, Iwata
H, Hurvitz SA, Wander SA, Danso M, Lu DR, Perkins Smith J, Liu Y,
et al: VERITAC-2: A phase III study of vepdegestrant, a PROTAC ER
degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.
Future Oncol. 20:2447–2455. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Campone M, De Laurentiis M, Jhaveri K, Hu
X, Ladoire S, Patsouris A, Zamagni C, Cui J, Cazzaniga M, Cil T, et
al: Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced
breast cancer. N Engl J Med. 393:556–568. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Petrylak DP, Garmezy B, Shen J, Rezazadeh
Kalebasty A, Sartor O, Dreicer R, Agarwal N, Hussain M, Percent I,
Heath E, et al: 1803P phase I/II study of bavdegalutamide, a PROTAC
androgen receptor (AR) degrader in metastatic castration-resistant
prostate cancer (mCRPC): Radiographic progression-free survival
(rPFS) in patients (pts) with AR ligand-binding domain (LBD)
mutations. Ann Oncol. 34:S973–S974. 2023. View Article : Google Scholar
|
|
56
|
Azad AA, Gurney H, Underhill C, Horvath L,
Voskoboynik M, Li X, King I, Shao L, Dai Y and Perabo F: Phase 1
study of HP518, a PROTAC AR degrader in patients with mCRPC:
Results on safety, pharmacokinetics, and anti-tumor activity.
Invest New Drugs. 43:435–445. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Syahputra EW, Lee H, Cho H, Park HJ, Park
KS and Hwang D: PROTAC delivery strategies for overcoming
physicochemical properties and physiological barriers in targeted
protein degradation. Pharmaceutics. 17:5012025. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wu CS, Li HP, Hsieh CH, Lin YT, Yi-Feng
Chang I, Chung AK, Huang Y, Ueng SH, Hsiao YC, Chien KY, et al:
Integrated multi-omics analyses of oral squamous cell carcinoma
reveal precision patient stratification and personalized treatment
strategies. Cancer Lett. 614:2174822025. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Buldak N, Veeraraghavan VP and Mony U:
Revolutionizing precision medicine in oral squamous cell carcinoma:
Harnessing 3D in vitro models for translation. Oral Oncol Rep.
11:1006222024. View Article : Google Scholar
|
|
60
|
Fisch AS, Pestana A, Sachse V, Doll C,
Hofmann E, Heiland M, Obermueller T, Heidemann J, Dommerich S,
Schoppe D, et al: Feasibility analysis of using patient-derived
tumour organoids for treatment decision guidance in locally
advanced head and neck squamous cell carcinoma. Eur J Cancer.
213:1151002024. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wu Y, Li X, Liu H, Yang X, Li R, Zhao H
and Shang Z: Organoids in the oral and maxillofacial region:
present and future. Int J Oral Sci. 16:612024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Millen R, De Kort WWB, Koomen M, van Son
GJF, Gobits R, Penning de Vries B, Begthel H, Zandvliet M,
Doornaert P, Raaijmakers CPJ, et al: Patient-derived head and neck
cancer organoids allow treatment stratification and serve as a tool
for biomarker validation and identification. Med. 4:290–310.e12.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Upadhyay V, Das S, Nehru A, Swetha US,
Vatsa PP, Chamoli A and Mandoli A: Advancing oral squamous cell
carcinoma research: The evolving role of patient-derived cell
lines, xenografts, and organoid models, 3. Biotech.
15:2952025.PubMed/NCBI
|
